Literature DB >> 15531902

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia.

S H Lim, Y Zhang, Z Wang, W V Esler, D Beggs, B Pruitt, P Hancock, M Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15531902     DOI： 10.1038/sj.bmt.1704742

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

Review 1.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

Review 2.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

3.  Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.

Authors:  Nicolò Compagno; Francesco Cinetto; Gianpietro Semenzato; Carlo Agostini
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

Review 4.  B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.

Authors:  R John Looney
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Persistence of Virus-Specific Antibody after Depletion of Memory B Cells.

Authors:  William A Langley; Andreas Wieland; Hasan Ahmed; Mohammed Ata Ur Rasheed; Carl W Davis; Jaturong Sewatanon; Scott N Mueller; Mark J Shlomchik; Veronika I Zarnitsyna; Rustom Antia; Rafi Ahmed
Journal:  J Virol       Date:  2022-04-11       Impact factor: 6.549

6.  Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

Authors:  Y L Kasamon; R J Jones; R A Brodsky; E J Fuchs; W Matsui; L Luznik; J D Powell; A L Blackford; A Goodrich; C D Gocke; R A Abrams; R F Ambinder; I W Flinn
Journal:  Ann Oncol       Date:  2009-10-30       Impact factor: 32.976

7.  Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma.

Authors:  Wei Zhang; Li Jiao; Dao-Bin Zhou; Ti Shen
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

8.  A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Authors:  Craig C Hofmeister; Nita Williams; Susan Geyer; Erinn M Hade; Mindy A Bowers; Christian T Earl; John Vaughn; Anissa Bingman; Kristina Humphries; Gerard Lozanski; Robert A Baiocchi; Samantha M Jaglowski; Kristie Blum; Pierluigi Porcu; Joseph Flynn; Sam Penza; Don M Benson; Leslie A Andritsos; Steven M Devine
Journal:  Leuk Lymphoma       Date:  2014-11-20

Review 9.  Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?

Authors:  Jennifer Worch; Olga Makarova; Birgit Burkhardt
Journal:  Cancers (Basel)       Date:  2015-01-29       Impact factor: 6.639

10.  The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

Authors:  Helena Marco; Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Fausta Catapano; Stella Burns; Afzal N Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  BMC Musculoskelet Disord       Date:  2014-05-25       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.